Literature DB >> 25039261

Association study of MTHFD1 coding polymorphisms R134K and R653Q with migraine susceptibility.

Heidi G Sutherland1, Heloise Hermile, Rebecca Sanche, Saras Menon, Rod A Lea, Larisa M Haupt, Lyn R Griffiths.   

Abstract

OBJECTIVE: There is evidence that folate metabolism has a role in migraine pathophysiology, particularly in the migraine with aura (MA) subtype. In this study, we investigate whether two non-synonymous single nucleotide polymorphisms (SNPs), rs1950902 (C401T; R134K) and rs2236225 (G1958A; R653Q), in MTHF dehydrogenase (MTHFD1) are associated with migraine in an Australian case-control population.
BACKGROUND: Increased plasma levels of homocysteine, one of the metabolites produced in the folate pathway, has been found to be a risk factor for migraine. There is also a genetic link: a common polymorphism (rs1801133, C667T) that reduces the catalytic activity of the enzyme that catalyzes the formation of homocysteine, methylenetetrahydrofolate reductase (MTHFR), is associated with an increase in risk of MA. MTHFD1 is a crucial multifunctional enzyme that catalyzes three separate reactions of the folate pathway and therefore variants in MTHFD1 may also influence migraine susceptibility.
METHODS: The R134K and R653Q variants in MTHFD1 were genotyped in an Australian cohort of 520 unrelated migraineurs (162 were diagnosed with migraine without aura [MO] and 358 with MA) and 520 matched controls. Data were analyzed for association with migraine and for interaction with the MTHFR C667T polymorphism.
RESULTS: We find no significant differences in genotype or allele frequencies for either SNP between migraineurs and controls, or when either MO or MA cases were compared with controls. In addition, these MTHFD1 polymorphisms did not appear to influence the risk of MA conferred by the MTHFR 667T allele.
CONCLUSIONS: We find no evidence for association of the MTHFD1 R134K and R653Q polymorphisms with migraine in our Australian case-control population. However, as folate metabolism appears to be important in migraine, particularly with respect to the aura component, future studies using high throughput methods to expand the number of SNPs in folate-related genes genotyped and investigation of interactions between SNPs may be justified.
© 2014 American Headache Society.

Entities:  

Keywords:  genetic association study; methenyltetrahydrofolate cyclohydrolase formyltetrahydrofolate synthase; migraine; single nucleotide polymorphism

Mesh:

Substances:

Year:  2014        PMID: 25039261     DOI: 10.1111/head.12428

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  5 in total

1.  MTHFD1 gene polymorphisms as risk factors involved in orofacial cleft: an independent case-control study and a meta-analysis.

Authors:  Jun Wu; Yafei Chen; Jun Pei; Jian Pan
Journal:  Int J Clin Exp Med       Date:  2015-05-15

2.  Independent and Interactive Influences of Environmental UVR, Vitamin D Levels, and Folate Variant MTHFD1-rs2236225 on Homocysteine Levels.

Authors:  Patrice Jones; Mark Lucock; Charlotte Martin; Rohith Thota; Manohar Garg; Zoe Yates; Christopher J Scarlett; Martin Veysey; Emma Beckett
Journal:  Nutrients       Date:  2020-05-18       Impact factor: 5.717

Review 3.  Is an "Epigenetic Diet" for Migraines Justified? The Case of Folate and DNA Methylation.

Authors:  Michal Fila; Cezary Chojnacki; Jan Chojnacki; Janusz Blasiak
Journal:  Nutrients       Date:  2019-11-14       Impact factor: 5.717

4.  Computational Functional Genomics-Based AmpliSeq™ Panel for Next-Generation Sequencing of Key Genes of Pain.

Authors:  Dario Kringel; Sebastian Malkusch; Eija Kalso; Jörn Lötsch
Journal:  Int J Mol Sci       Date:  2021-01-16       Impact factor: 5.923

5.  Association of Maternal Dietary Habits and MTHFD1 Gene Polymorphisms With Ventricular Septal Defects in Offspring: A Case-Control Study.

Authors:  Xinli Song; Yiping Liu; Tingting Wang; Senmao Zhang; Mengting Sun; Jing Shu; Jianhui Wei; Jingyi Diao; Jinqi Li; Yihuan Li; Letao Chen; Ping Zhu; Jiabi Qin
Journal:  Front Pediatr       Date:  2022-02-02       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.